Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Cytokinetics (CYTK) reported Q3 2025 results marked by continued investment ahead of potential commercialization. Total revenue was $1.936 million, primarily from collaboration revenue. Operating expenses rose to $168.7 million, driving an operating loss of $166.8 million. Net loss widened to $306.2 million, reflecting a $121.2 million debt conversion expense tied to convertible notes activity.
Liquidity remained strong with cash, cash equivalents and investments of roughly $1.3 billion as of September 30, 2025. The balance sheet shows $1.958 billion in total liabilities, including $889.5 million in convertible notes, $158.7 million in term loans, and liabilities related to revenue participation agreements. Stockholders’ deficit was $(521.1) million. Year-to-date cash used in operations was $367.4 million.
The company continues late-stage development programs and notes a PDUFA target action date of December 26, 2025 for the NDA for aficamten in obstructive HCM. Common shares outstanding were 122,264,929 as of November 3, 2025.
Cytokinetics (CYTK) reported an insider transaction on a Form 4. The company’s President & CEO and Director reported a bona fide gift (Code G) of 2,000 shares of common stock on 11/05/2025 at a price of $0.
Following the transaction, the reporting person beneficially owns 356,108 shares directly, plus 2,083 shares held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held indirectly by The Brittany Blum 2003 Irrevocable Trust.
Cytokinetics, Incorporated furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025. The company provided these results via a press release dated November 5, 2025, which is included as Exhibit 99.1.
The information under Item 2.02 and Exhibit 99.1 is being furnished, not filed, and will not be incorporated into future Securities Act or Exchange Act filings unless expressly stated by the company.
Cytokinetics (CYTK) reported an insider transaction by its EVP, Research & Development. On 11/04/2025, the officer exercised 2,295 incentive stock options at $10.60 per share (code M) and sold 2,295 common shares at $59.55 (code S). Following these transactions, the officer held 140,610 common shares directly and retained 6,600 derivative securities (options).
Cytokinetics (CYTK) disclosed an insider transaction via Form 4. President & CEO and Director Mr. Blum reported a sale of 5,000 shares of common stock on 10/30/2025 at a price of $62.86 per share (transaction code S). Following the sale, he beneficially owns 358,108 shares directly.
He also reports indirect holdings of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust. No derivative securities were reported in this filing.
Cytokinetics (CYTK) reported a Form 4 for a director. On 10/27/2025, the insider exercised 4,375 stock options at $10 and sold 4,375 common shares at $58.68 the same day. After these transactions, the director directly owned 32,444 shares.
The option exercised was a non-qualified stock option with a $10 exercise price, first exercisable on 02/04/2016 and expiring 01/04/2026; it is now fully exercised.
Cytokinetics (CYTK) disclosed a Form 4 for its EVP of Research & Development reporting insider transactions on 10/21/2025. The officer exercised 2,105 non-derivative shares via an option at $10.60 per share (code M) and sold 2,105 shares at $58.22 (code S) on the same date. Following these transactions, the reporting person directly holds 140,610 shares of common stock. A non-qualified stock option with an exercise price of $10.60, initially exercisable on 03/28/2017 and expiring on 02/28/2027, shows 1,000 derivative securities beneficially owned after the reported activity.
Cytokinetics, Inc. (CYTK) reported an insider transaction on Form 4. A company director acquired 99 shares of common stock on 10/15/2025 at a price of $62.8 per share. The filing notes the transaction code A (1), with the footnote stating, “Director equity in lieu of cash retainer program,” indicating this was a stock grant in place of cash fees.
Following the transaction, the director now beneficially owns 32,444 shares, held directly. No derivative securities were reported in this filing.
Cytokinetics (CYTK) reported an insider transaction. President & CEO sold 5,000 shares of common stock on 10/16/2025 at $60.03 per share. Following the sale, the reporting person beneficially owns 363,108 shares directly.
Additional indirect holdings are disclosed as 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.
Cytokinetics (CYTK) director reported acquiring common stock. On 10/15/2025, the director acquired 99 shares at $62.8 per share under the director equity in lieu of cash retainer program. After this transaction, the director beneficially owns 30,873 shares, held directly.